Circulating Tumor DNA (CtDNA) Methylation Market Report 2025

The circulating tumor DNA (CtDNA) methylation market size has grown rapidly in recent years. It will grow from $1.3 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. Growth in the historic period was driven by the rising number of clinical studies on ctDNA methylation, increasing adoption of precision medicine strategies, greater use of biomarkers for prognosis, growing publication of research supporting ctDNA methylation applications, and wider implementation of advanced laboratory automation.

The circulating tumor DNA (CtDNA) methylation market size is expected to see rapid growth in the next few years. It will grow to $2.43 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. Growth in the forecast period is expected to be supported by the expansion of point-of-care ctDNA testing solutions, increased adoption of telemedicine for remote diagnostics, rising global awareness of epigenetic biomarkers, growth in cross-industry partnerships, and greater collaboration between research institutes and diagnostic companies. Key trends anticipated for the forecast period include integration of bioinformatics for methylation profiling, advancements in treatment response monitoring, innovation in population-level screening programs, adoption of automated sample processing systems, and development of targeted therapy guidance.

The rising prevalence of cancer is expected to drive the growth of the circulating tumor DNA (ctDNA) methylation market in the coming years. Cancer rates are increasing due to aging populations and lifestyle-related risk factors such as unhealthy diets, tobacco use, and lack of physical activity, which contribute to genetic mutations and tumor formation. Circulating tumor DNA methylation assays support early and non-invasive cancer detection, enable accurate monitoring of disease progression, and assist in making personalized treatment decisions, leading to timely and effective clinical interventions. For example, in May 2024, the National Cancer Institute, a United States-based government agency, reported that the number of cancer survivors in the United States is projected to grow from eighteen point one million in 2022 to twenty six million by 2040. Therefore, the increasing prevalence of cancer is contributing to the expansion of the ctDNA methylation market.

Leading companies in the circulating tumor DNA methylation market are developing multi-cancer early detection blood tests that analyze cancer-specific methylation patterns in ctDNA to allow for early and non-invasive detection of various cancer types. These tests improve clinical outcomes by identifying distinct methylation signatures, supporting timely diagnosis and guiding precise treatment strategies. For instance, in September 2025, Exact Sciences Corporation, a United States-based molecular diagnostics company, introduced Cancerguard, a multi-cancer early detection blood test that incorporates ctDNA methylation analysis. Cancerguard detects specific methylation patterns across more than fifty types of cancer, offering sensitive and non-invasive detection while delivering useful insights for clinicians to support ongoing monitoring and treatment planning. This development marks a significant advancement in early cancer detection and precision-based care.

In January 2023, Agilent Technologies Incorporated, a United States-based provider of laboratory instruments, software, services, and consumables, acquired Avida Biomed Incorporated for an undisclosed amount. The acquisition aims to integrate Avida Biomed’s target enrichment technologies to enhance Agilent’s precision oncology offerings and broaden its role in molecular diagnostics. Avida Biomed is a biotechnology company based in the United States that develops circulating tumor DNA methylation technologies for sensitive, non-invasive, and targeted early cancer detection.

Major players in the circulating tumor DNA (ctDNA) methylation market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, Qiagen N.V., Natera Inc., BGI Group, Guardant Health Inc., Invitae Corporation, Grail Inc., Genetron Holdings Limited, Buing Rock Biotech Limited, Zymo Research Corp, Agena Bioscience Inc., Phalanx Biotech Group Inc., Epigenomics Ag, EpigenDx Inc., Singlera Genomics Inc., Sampled.

North America was the largest region in the circulating tumor DNA (CtDNA) methylation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in circulating tumor DNA (ctDNA) methylation report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the circulating tumor DNA (ctDNA) methylation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Circulating tumor DNA (ctDNA) methylation refers to the addition of methyl groups to DNA fragments released by tumor cells into the bloodstream. This epigenetic modification influences gene expression and is frequently altered in cancer cells. Detecting ctDNA methylation patterns in blood enables non-invasive cancer diagnosis, monitoring of tumor progression, and evaluation of treatment response through liquid biopsy techniques.

The primary product types in the circulating tumor DNA (ctDNA) methylation market include reagents and kits, instrumentation, software and bioinformatics solutions, and services. Reagents and kits consist of consumable materials used in ctDNA methylation analysis, such as those for DNA extraction, bisulfite conversion, methylation detection, library preparation, and targeted enrichment. Key technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, and other methods. Sample types include blood, urine, saliva, tissue, and others. Major applications encompass oncology, cardiovascular diseases, neurological disorders, infectious diseases, and additional areas. End-users include hospitals and clinics, research and diagnostic laboratories, pharmaceutical and biotechnology companies, and academic institutions.

The circulating tumor DNA (ctDNA) methylation market research report is one of a series of new reports that provides circulating tumor DNA (ctDNA) methylation market statistics, including circulating tumor DNA (ctDNA) methylation industry global market size, regional shares, competitors with a circulating tumor DNA (ctDNA) methylation market share, detailed circulating tumor DNA (ctDNA) methylation market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor DNA (ctDNA) methylation industry. The circulating tumor DNA (ctDNA) methylation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The circulating tumor DNA (ctDNA) methylation market consists of revenues earned by entities by providing services such as early cancer detection services, prognostic testing services, clinical trial support services, liquid biopsy services, and epigenetic profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The circulating tumor DNA (ctDNA) methylation market also includes sales of bisulfite conversion kits, methylation arrays, capillary electrophoresis systems, methyl-capture enrichment kits, and targeted methylation sequencing panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.